AU599027B2 - Use of an aqueous, stabilised chlorite matrix solution for infectious conditions - Google Patents
Use of an aqueous, stabilised chlorite matrix solution for infectious conditions Download PDFInfo
- Publication number
- AU599027B2 AU599027B2 AU56842/86A AU5684286A AU599027B2 AU 599027 B2 AU599027 B2 AU 599027B2 AU 56842/86 A AU56842/86 A AU 56842/86A AU 5684286 A AU5684286 A AU 5684286A AU 599027 B2 AU599027 B2 AU 599027B2
- Authority
- AU
- Australia
- Prior art keywords
- tcdo
- chlorite
- aqueous
- sodium
- infectious
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 23
- 230000002458 infectious effect Effects 0.000 title claims abstract description 10
- 229910001919 chlorite Inorganic materials 0.000 title claims description 14
- 229910052619 chlorite group Inorganic materials 0.000 title claims description 14
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 title claims description 13
- 239000011159 matrix material Substances 0.000 title claims description 10
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 241000233866 Fungi Species 0.000 claims abstract description 4
- 241000700605 Viruses Species 0.000 claims abstract description 4
- 244000045947 parasite Species 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000186779 Listeria monocytogenes Species 0.000 claims description 3
- 229940095731 candida albicans Drugs 0.000 claims description 3
- 241000204031 Mycoplasma Species 0.000 claims description 2
- DLLFWZVLRWBBQC-UHFFFAOYSA-M [Na+].[Na+].Cl[O-].[O-]Cl=O Chemical compound [Na+].[Na+].Cl[O-].[O-]Cl=O DLLFWZVLRWBBQC-UHFFFAOYSA-M 0.000 claims description 2
- MWUBHCHCZJPTJK-UHFFFAOYSA-N [Na].Cl(=O)(=O)OS(O)(=O)=O Chemical compound [Na].Cl(=O)(=O)OS(O)(=O)=O MWUBHCHCZJPTJK-UHFFFAOYSA-N 0.000 claims description 2
- 229960001922 sodium perborate Drugs 0.000 claims description 2
- PFUVRDFDKPNGAV-UHFFFAOYSA-N sodium peroxide Chemical compound [Na+].[Na+].[O-][O-] PFUVRDFDKPNGAV-UHFFFAOYSA-N 0.000 claims description 2
- MWNQXXOSWHCCOZ-UHFFFAOYSA-L sodium;oxido carbonate Chemical compound [Na+].[O-]OC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-L 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims 1
- 229940045872 sodium percarbonate Drugs 0.000 claims 1
- 241001430197 Mollicutes Species 0.000 abstract description 2
- VOWOEBADKMXUBU-UHFFFAOYSA-J molecular oxygen;tetrachlorite;hydrate Chemical compound O.O=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O.[O-]Cl=O VOWOEBADKMXUBU-UHFFFAOYSA-J 0.000 description 34
- 206010070834 Sensitisation Diseases 0.000 description 10
- 230000008313 sensitization Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000028996 humoral immune response Effects 0.000 description 5
- 210000001539 phagocyte Anatomy 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- NHYCGSASNAIGLD-UHFFFAOYSA-N Chlorine monoxide Chemical compound Cl[O] NHYCGSASNAIGLD-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- QBWCMBCROVPCKQ-UHFFFAOYSA-M chlorite Chemical compound [O-]Cl=O QBWCMBCROVPCKQ-UHFFFAOYSA-M 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Abstract
The solution is administered intravenously and/or locally in infectious conditions caused by parasites, fungi, bacteria, viruses and/or mycoplasmas.
Description
599027
AUSTRALIA
Patentis Act COMPLETE SPECIFICATION
(ORIGINAL)
Class Int. Ciass Application Number: Lodged:5-842 '3 Complel 000 Priority SRelated 0- 0 te Specification Lodged: Accept Ad: Publishcd: EThis documnt contains the amendmtS made und -T Section 49 and is correct Our LODGED AT SU-FrFCE 3 P A P R198 6 Art: 0 00 0 c' 0 0000 o 0 0 00 APPLICANT'S REF.: 4476 B2 OXO CHEMIE GmnbH Name(s) of Applicant(s): Address(es) of Applicant(s):
II
I
as'' a a Actual Inventor(s): MaaBstrasse 24, 6900 Heidelberg, Federal Republic of Germany Dr. Friedrich W. Kuhne Prof. Dr. Erich F. Elstner Dr. Hans-Heinrich Kuhne PHILLIPS, ORMOND3 AND FITZPATRICK Patent and Trade Mark Attc-r u 367 Collins Street Melbourne, Australia, 3000 Address for Service is: Complete Specification for the invention entitled: "USE OF AN AQUEOUS, STABILISED CHLORITE MATRIX SOLUTION FOR INFECTIOUS CONDITIONS" The following statement is a full description of this invention, including thle best method of performing it known to applicant(s): P 19/3/84
A
-2- 2 The invention relates to' the use of an aqueous solution of a stabilized chlorite matrix for intravenous zno toj.ii-. administration in infectious conditions caused by parasites,., fungi, bacteria, viruses and/or mycoplasmas. The chlorite matrix used herein the claims and descriptions is described as a negatively charged matrix of chlorite which is chemically stabilized with oxygen or another element of Group VI a and b of the periodic table.
.Stabilized chlorite matrices containing activated oxygen are 1o disclosed in German Patent No. 3,213,389 for which the corresponding US Patent is No. 4,,507,285.
It has been found that, irrespective of their oxygen I, content, stabilized chlorite matrices, which can be activated using bioactivators to give compounds with 4404 S. electron affinity, amplify the "OXIDATIVE BURST" response of phagocytes. It is known from the Literature ('Enhancement of Phagocytosis-Associated Metabolism as a Manifestation of Macrophage Activation' by Richard B Johnston, Dr in Lymphokines, 3:33-56, 1981, Academic Press), that there is a close correlation between the extent of the oxidative response to phagocytosis and the ability to kill microorganisms intracellularly. In vitro, the chemiluminescence associated .with the 'OXIDATIVE BURST' represents a quantiti-:e measure of phagocyte stimulation.
o Measurements in which human granulocytes in whole blood were incubated with non-specifically and specifically opsonized bacteria pathogenic for humans show that addition of o stabilized chlorite matrix solution may result in an increase in the chemiluminescence to 1.7 17 times the 0o control figure, as long as heme-containing bioactivators are dissolved and freely available in the meir'm.
Example 1 Effect of TCDO on -Phagkineiand isa'.monocytogenes Infection The phagocyte stj iaon measured in vitro has been confirmed b gocyte activation (phagokinesis) recorded in vth. c C57 Bl/6 nmous the phagokinoeSis iuedby Sr ,/AR 2a One aspect of the present invention is to provide a method of treating infectious conditions caused by parasites, fungi, bacteria, viruses and mycoplasma which comprises administering intraveneously an effective amount of an aqueous therapeutic solution of a chlorite matrix with a chlorite concentration of' 12 to 72 pmol C102-/ml prepared by reaction of the-following components: sodium chlorite sodium hypochlorite solution chloryl sulfuric acid sodium perborate or So percarbonate and 0 sodium peroxide.
0 00 o The following examples are provided to illustrate the So present invention but are not intended to restrict the scope o 0o of the invention in any way.
Example 1 Effect of Tetrachlorodecaoxide (TCDO) On Phagokinesis and Listeria monocytogenes Infection The tetrachlorodecaoxygen-anion complex (TCDO) I constitutes a new chloro-oxygen compound.
The phagocyte stimulation measured in vitro has been confirmed by phagocyte activation (phagokinesis) recorded in vivo. In the C57 B1/6 mouse the phagokinesis induced by 0975v
AR
L.
3 administration of a solution of stabilized chlorite matrix (15.5 m mol/1) (single i.p. doses of 0.2 0.5 ml of chlorite matrix per kg of body weight one hour after i.v.
5 administration of 4.5 x 10 Listeria monocytogenes bacteria, corresponding to an infectious lethal dose for of the animals (ILD 80 resulted in a significant increase in the Listeria monocytocenes clearance in the spleen, and in survival of all the animals.
Example 2 Effect ofQ(TCDO) on Humoral and cellular Immune Responses after Candida albicans Infection t An investigation into whether TCDO could influence i .o experimental infections with aerobic and anaerobic S microorganisms was carried out. Experiments were performed I to instigate whether TCDO could modulate humoral or cellular immune responses in vivo which may contribute to host defence reactions against infection.
S O Material and Methods 2.1 Experimental animals iFor all assays, male mice of the inbred line Balb/cABOM (Bomholtgard Ltd, Ry, Denmark) of 20 1 g bodyweight were used.
2.2 TCDO TCDO (WF10, code number of product in development) was available in an isotonic water solution of 15.5 mmol/l.
TCDO was diluted with saline immediately before use. If not 0 otherwise stated, the volume of all intravenous injections S- was 0.5 ml.
2.3 Experimental infection Washed cells of Candida albicans ATCC 10231 of the log growth phase in both containing 1% glucose (E Merck, Darmstadt, FR Germany) were injected intravenously in doses 4 of 6 x 10 Candida cells per 0.25 ml,, corresponding to a dose which was lethal for 75% of the animals (ILD 7 5) as 4 previously determined under identical standardized
L
4 conditions For these Candida cells, the mean inhibitory and bactericidal concentrations (MIC and MBC, resp.) of TCDO were found to be above 7.6 mmol/l.
The strictly anaerobically growing strain of Peptostreptococcus intermedius VA 16886, isolated from biopsy material, was used for infections with an anaerobes.
MIC and MBC, in a thioglocycollate medium (Oxoid, Basingstoke, Hampshire, UK) were found to be 0.49 mmol/l and S1.94 mmol/l in broth containing glucose and, in the presence S 10 of additionally 10% foetal calf serum, 0.49 mmol/l and 0.97 mmol/l, respectively.
Germs were cultivated on Schadler anaerobic agar (Oxoid) for 48 h at 37 0 C, rinsed out and washed once with saline concentration suspended in thioglycollate medium Sadjusted to a concentration of 101 cells per ml. Volumes of 0.1 ml were injected intramuscularly (randomized infection) into the hindleg at the same site where 0.05 ml of a 5% solution of lactic acid had been applied the day before. Periods of exposure to air were kept to a barest minimum: infection was carried out by 2 technical assistants within 15 min and bacteria were handled no longer than 30-40 min. Based on pilot experiments under identical conditions, Sthe infectious dose corresponded to an ILD 75 85 4 2.4 Humoral immune response The influence of TCDO on the humoral immune response was evaluated by the Jerne plaque assay technique [13], modified by Cunningham and Szenberg The animals were i immunized by intraperitoneal injections of 1 x 104 sheep red blood cells (SRBC) in 0.5 ml saline. The number of direct plaque forming, immunoglobulin (lg)M producing spleen cells (DPFC) was evaluated on day 3 and that of indirect plaque forming IgG producing spleen cells (IPFC) was assessed on day 7 after immunization and was calculated for 104 spleen cells. Different doses of TCDO were given 1 h before sensitization or in another series of experiments 1 day before evaluation, on days 2 and 6 after sensitization in the case of DPFC and IPFC, respectively.
Cellular immunity The ootpad swelling reaction (FPSR) in mice [15] has been shown to correlate with the cellular immune response 4 For sensitization, doses of 1 x 10 SRBC in 0.5 ml saline were injected intravenously and for challenge 1 x SRBC in 0.04 ml saline into the left hind footpad 4 days later (saline for controls). The difference in the bilateral skin thickness (A mm) before and 24 h after challenge, was taken for evaluation (Oditest 00 T6, I0 Kroeplin, Schluchtern, FR Germany). TCDO was given in single doses either on day 0, 1 h before sensitization, or on day 3, or on day 4, 1 h before the challenge injection.
In separate assays, the influence of repeated TCDO applications was examined.
o Results 2.6 Influence of TCDO on experimental infection with Candida Albicans t In an initial series of experiments, different doses of TCDO were given only once, 1 h after infection. In 2 assays performed on different days, the ILD 75 expected from previous experiments was determined as ILD and 73.3 ILD76 in the control animals. The experiments showed a i 76.7 steep increase in the survival rate up to a dose of 3.1 imol/kg b.w. Higher doses, however, up to 1.8.6 pmol/kg b.w. decreased the survival rate below the control value.
S' 2.7 TCDO treatment of experimental anaerobic infections Experimental infections with Peptostreptococcus intermedius w're treated with single intravenous injections of TCDO 1 h after infection in doses of 3.1 and 12.4 pmol/kg b.w. TCDO. The control mice received saline. Both TCDO doses increased the survival rate in comparison to the saline treated controls.
2.8 Influence of TCDO on humoral immune response A single dose of 3.1 pmol/kg b.w. TCDO given 1 h before sensitization increased the DPFC response significantly. This effect was even more pronounced when 6 TCDO was injected 2 days after sensitization, 1 day before evaluation.
The high dose of 18.6 pmol/kg b.w. had no significant effect on the DPFC response in comparison to controls, irrespective of the time of TCDO administration, either 1 h before or 2 days after sensitization, and in contrast to the fact that this TCDO dose was already inhibitory in experimental Candida infections.
On the other hand, in the case of late TCDO 0o administrations, the higher dose of TCDO had a significantly lower effect in comparison to the lower dose. Similar results were obtained in evaluating the IPFC response.
S Single TCDO doses of 3.1 pmol/kg given 1 h before or 6 days after sensitization, i.e. 1 day before evaluation, resulted in an increased IPFC response.
2.9 Effect on cellular immunity The low single dose of 3.1 pmol/kg b.w. TCDO induced a highly significant FPSR irrespective of the time of administration, given either as a single dose 1 h before or 4 3 days after sensitization. TCDO treatment of the mice 1 h before challenge had no effect.
When TCDO was injected intraperitoneally at the low dose 1 h before sensitization, a slight but significant increase of 5% was observed in FPSR, whereas a high TCDO dose which had shown negative immunomodulation showed no effect in comparison to the controls.
Claims (4)
1. A method of treating infectious conditions caused by parasites, fungi, bacteria, viruses and mycoplasma which comprises administering, intraveneously an effective amount of an aqueous therapeutic solution of a chlorite matrix with a chlorite concentration of 12 to 72 pmol C102 /ml prepared by reaction of the following components: sodium chlorite sodium hypochlorite solution chloryl sulfuric acid sodium perborate or percarbonate and sodium peroxide.
2. A method as claimed in claim 1 wherein the infectious condition is caused by Listeria monocytogenes.
3. A method as claimed in claim 1 wherein the infectious condition is caused by Candida albicans.
4. A method as claimed in claim 1 substantially as hereinbefore described with reference to any one of the S examples. DATED: 22 January, 1990 SOXO CHEMIE GmbH By their Patent Attorneys: PHILLIPS ORMONDE FITZPATRICK AR j I k
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3515749 | 1985-05-02 | ||
| DE19853515749 DE3515749A1 (en) | 1985-05-02 | 1985-05-02 | USE OF A STABILIZED CHLORITE MATRIX SOLUTION IN INFECTIOUS CONDITIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5684286A AU5684286A (en) | 1986-11-06 |
| AU599027B2 true AU599027B2 (en) | 1990-07-12 |
Family
ID=6269618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU56842/86A Ceased AU599027B2 (en) | 1985-05-02 | 1986-04-30 | Use of an aqueous, stabilised chlorite matrix solution for infectious conditions |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0200157B1 (en) |
| JP (1) | JPS6230716A (en) |
| AT (1) | ATE77956T1 (en) |
| AU (1) | AU599027B2 (en) |
| CA (1) | CA1268713A (en) |
| DE (2) | DE3515749A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3528379A1 (en) * | 1985-08-07 | 1987-02-12 | Peter Berger | Composition for the treatment of aqueous systems and for the regeneration of body cells |
| DE3600931A1 (en) * | 1986-01-15 | 1987-07-16 | Oxo Chemie Gmbh | Formulation of chlorite matrices in solution |
| DE4208828A1 (en) * | 1992-03-19 | 1993-09-23 | Oxo Chemie Gmbh | USE OF A CHEMICALLY STABILIZED CHLORITE MATRIX FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF HIV INFECTIONS |
| US5252343A (en) * | 1992-03-20 | 1993-10-12 | Alcide Corporation | Method and composition for prevention and treatment of bacterial infections |
| US6099855A (en) * | 1992-06-25 | 2000-08-08 | Bioxy, Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
| US5830511A (en) * | 1992-06-25 | 1998-11-03 | Bioxy Inc. | Therapeutic, production and immunostimulatory uses of biocidal compositions |
| WO1999017787A2 (en) * | 1997-10-06 | 1999-04-15 | Oxo Chemie Ag | Use of a chemically-stabilized chlorite solution for inhibiting an antigen-specific immune response |
| RU2147889C1 (en) * | 1999-04-26 | 2000-04-27 | Солодовникова Елена Сергеевна | Preparation and method of treating patient with urethro-genital infection and herpes |
| MXPA02001724A (en) * | 1999-08-18 | 2004-09-06 | Oxo Chemie Ag | Chemically-stabilized chlorite solutions for treating cancer and other diseases. |
| DE10127729C2 (en) | 2001-06-07 | 2003-05-28 | P & W Invest Vermoegensverwalt | Stable aqueous chlorine-oxygen solution which is essentially free of chlorite, process for its preparation and its use |
| JP5371443B2 (en) * | 2005-12-22 | 2013-12-18 | ニューラルタス ファーマシューティカルズ，インコーポレイテッド | Chlorite formulations and methods and uses of this preparation |
| EP2164502A1 (en) | 2007-06-01 | 2010-03-24 | Dimethaid AG | Use of wf10 for treating allergic asthma, allergic rhinitis and atopic dermatitis |
| JP2015071581A (en) * | 2013-05-20 | 2015-04-16 | 本部三慶株式会社 | Virus disinfectant containing chlorous acid water |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5684186A (en) * | 1985-05-02 | 1986-11-06 | Oxo Chemie Ag | Aqueous chlorite matrix solution |
| AU5684086A (en) * | 1985-05-02 | 1986-11-06 | Oxo Chemie Ag | Use of an aqueous chlorite matrix solution for the treatment of tumors |
| AU566830B2 (en) * | 1983-02-02 | 1987-10-29 | Peter Berger | Method for producing a modified aqueous chlorite solution, solution produced thereby and utilization thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4296102A (en) * | 1980-06-12 | 1981-10-20 | Felipe Laso | Method of combating amebiasis in humans |
| US4296103A (en) * | 1980-08-08 | 1981-10-20 | Felipe Laso | Stabilized solution of chlorine oxides |
| DE3213389A1 (en) * | 1982-04-10 | 1983-10-20 | Friedrich-Wilhelm Dr. 7107 Neckarsulm Kühne | STABILIZED ACTIVATED OXYGEN AND MEDICINAL PRODUCTS CONTAINING THIS STABILIZED ACTIVATED OXYGEN |
-
1985
- 1985-05-02 DE DE19853515749 patent/DE3515749A1/en not_active Withdrawn
-
1986
- 1986-04-24 DE DE8686105648T patent/DE3685908D1/en not_active Expired - Lifetime
- 1986-04-24 EP EP86105648A patent/EP0200157B1/en not_active Expired - Lifetime
- 1986-04-24 AT AT86105648T patent/ATE77956T1/en not_active IP Right Cessation
- 1986-04-30 AU AU56842/86A patent/AU599027B2/en not_active Ceased
- 1986-05-02 JP JP61101260A patent/JPS6230716A/en active Granted
- 1986-05-02 CA CA000508199A patent/CA1268713A/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU566830B2 (en) * | 1983-02-02 | 1987-10-29 | Peter Berger | Method for producing a modified aqueous chlorite solution, solution produced thereby and utilization thereof |
| AU5684186A (en) * | 1985-05-02 | 1986-11-06 | Oxo Chemie Ag | Aqueous chlorite matrix solution |
| AU5684086A (en) * | 1985-05-02 | 1986-11-06 | Oxo Chemie Ag | Use of an aqueous chlorite matrix solution for the treatment of tumors |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0200157A2 (en) | 1986-11-05 |
| JPS6230716A (en) | 1987-02-09 |
| EP0200157B1 (en) | 1992-07-08 |
| JPH0234326B2 (en) | 1990-08-02 |
| DE3685908D1 (en) | 1992-08-13 |
| CA1268713A (en) | 1990-05-08 |
| DE3515749A1 (en) | 1986-11-06 |
| AU5684286A (en) | 1986-11-06 |
| ATE77956T1 (en) | 1992-07-15 |
| EP0200157A3 (en) | 1989-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU599027B2 (en) | Use of an aqueous, stabilised chlorite matrix solution for infectious conditions | |
| JP7758366B2 (en) | Radical generating catalyst, method for producing radicals, method for producing oxidation reaction products, pharmaceuticals, and agricultural and livestock pharmaceuticals | |
| JP2676080B2 (en) | Non-antibacterial tetracycline composition | |
| FI114852B (en) | Acidified nitrate as antimicrobial agent | |
| US20210023538A1 (en) | Radical generating catalyst, method for producing radical, method for producing oxidation reaction product, drug, and drug for agriculture and livestock | |
| CA2195082A1 (en) | Electrically hydrolyzed salines as in vivo microbicides for the treatment of cardiomyopathy and multiple sclerosis | |
| US3329607A (en) | Method for the biological purification of drinking water | |
| JP2003277203A (en) | Antibacterial agent mainly composed of fluorotannins | |
| JPH01311021A (en) | Method for preventing propagation of aids generated by transfusion | |
| Ammar et al. | Dermaseptin, a peptide antibiotic, stimulates microbicidal activities of polymorphonuclear leukocytes | |
| NO980793L (en) | Use of aminoadamantane compound as immune regulators | |
| CN103907598A (en) | Chlorine disinfectant effervescent tablet | |
| AU2005249370B2 (en) | Ozonized pharmaceutical composition and method | |
| EP1154953B1 (en) | Peroxochloric acid, derivatives and anions, salts thereof, method for producing them and use of the same | |
| Exon et al. | Immunotoxicologic evaluation of chlorine-based drinking water disinfectants, sodium hypochlorite and monochloramine | |
| EP1687238B1 (en) | Reactive chlorine compounds, the derivatives, anions, and salts thereof, method for the production thereof, and use thereof | |
| US2927058A (en) | Method of producing antisepsis by beta amylose trhodide | |
| Juhr et al. | Intestinal accumulation of urea in germ-free animals-a factor in caecal enlargement | |
| EP3945072A1 (en) | Systems and methods for the large scale activation of water and uses of activated water | |
| Chin | Neutralization of shellfish poison by chemical disinfectants | |
| Musher et al. | Further observations on the potentiation of the antibacterial effect of methenamine by acetohydroxamic acid | |
| OHNISHI et al. | Mutagenicity of anti-trypanosomal drug, Ro 7-1051, in Escherichia coli | |
| JP5963143B2 (en) | Cucumber powdery mildew control agent and control method | |
| JP2676093B2 (en) | Animal feed composition | |
| RU2232711C1 (en) | Method of production of xenon difluoride, its rectification and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |